Please check your internet connection and try again.
# Hepamerz (L-Ornithine L-Aspartate - LOLA)
## Overview
L-Ornithine L-Aspartate (LOLA) is a stable salt of two amino acids that serves as a substrate for the urea cycle and glutamine synthesis. It is used to stimulate ammonia detoxification in the liver and muscle tissue to help manage hyperammonemia associated with hepatic encephalopathy (HE).
## Primary Indications
* Management of hyperammonemia in liver cirrhosis.
* Treatment of latent and manifest hepatic encephalopathy.
## Adult Dosing
* **Oral (Granules):** 3 g (one sachet) 3 times daily. Some protocols suggest up to 3 g 4 times daily for severe cases.
* **Intravenous (Ampoules):** 10 g to 20 g (up to 4 ampoules) daily via slow infusion, diluted in at least 500 mL of appropriate IV fluid. Maximum infusion rate should not exceed 5 g per hour to prevent nausea/vomiting.
## Pediatric Dosing
* **Safety/Efficacy:** Pediatric safety and dosing are not well-established. Use is generally restricted to specialized hepatology centers under specific protocols. Dosage should be weight-based and determined by the attending specialist.
## Dose Adjustments
* **Renal Impairment:** Use caution in patients with severe renal insufficiency (serum creatinine > 3 mg/dL). Dosing may require reduction; clinical judgment is required as data is limited.
* **Hepatic Impairment:** No dose reduction required; however, monitor closely for signs of worsening encephalopathy or fluid overload during IV administration.
## Contraindications
* Hypersensitivity to L-ornithine or L-aspartate.
* Severe renal impairment (creatinine > 3 mg/dL).
* Presence of severe, untreated electrolyte disturbances.
## Adverse Effects
* **Common:** Nausea, vomiting, stomach pain, diarrhea, and flatulence.
* **Rare:** Limb pain, pruritus/skin rash, and anaphylactoid reactions.
* **Administration-related:** Injection site irritation if infused too rapidly.
## Key Drug Interactions
* No major high-risk pharmacokinetic drug-drug interactions are documented. However, it should be used cautiously with medications known to cause nephrotoxicity or that modulate urea cycle pathways. Always verify complete current medication list to rule out additive side effects.
## Monitoring
* **Ammonia levels:** Serial monitoring of venous or arterial ammonia levels to assess therapeutic response.
* **Renal function:** Serum creatinine and BUN, especially in patients receiving high-dose IV therapy.
* **Electrolytes:** Periodic checks, especially during prolonged IV administration.
* **Clinical Status:** Assessment of mental status (e.g., West Haven Criteria) and neurological function.
## Clinical Pearls
* **Mechanism:** LOLA acts by providing substrates for the urea cycle (in hepatocytes) and the glutamine synthesis pathway (in skeletal muscle), effectively lowering blood ammonia.
* **Administration:** Oral granules should be dissolved in a large glass of liquid (water, juice, tea) with or after meals.
* **IV Precautions:** IV infusion must be performed slowly to prevent gastrointestinal upset. Do not mix with other medications in the same IV line.
* **Clinical Efficacy:** While utilized in many regions, evidence for efficacy in reversing manifest HE can vary; it is often used as an adjunct rather than a monotherapy.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines and drug labeling may vary by country and institution. Always consult the latest local package insert, clinical pharmacists, or institutional protocols before prescribing or administering medication.
